Retroviral vector-transduced autologous T cells to express anti-ALPP CARs (TCRCure Biopharma Corporation)

N/A

Report date: 2024/10/24 20:00:07

Base Information

Drug NameRetroviral vector-transduced autologous T cells to express anti-ALPP CARs (TCRCure Biopharma Corporation)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector

Mechanisms of ActionAlkaline phosphatase, placental type modulators

TargetsAlkaline phosphatase, placental type

Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesThe Second Affiliated Hospital of Army Medical University

China Registration ClassN/A

Develop Information

Active CompaniesThe Second Affiliated Hospital of Army Medical University

Inactive CompaniesN/A

Active IndicationsSolid tumoursEndometrial NeoplasmsOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A